Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919982 · ClinicalTrials.gov registry record
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
A clinical trial of Nonvalvular Atrial Fibrillation, sponsored by Baim Institute for Clinical Research.
- Completed
- Registry status
- 817
- Enrollment target
- 20
- Study locations
NCT02919982: Completed study of Nonvalvular Atrial Fibrillation, sponsored by Baim Institute for Clinical Research.
NCT02919982 is a study of Nonvalvular Atrial Fibrillation that has completed, run by Baim Institute for Clinical Research. The registered enrollment target is 817 participants, below the 109,128-participant average among 5 other Nonvalvular Atrial Fibrillation trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02919982, a study of Nonvalvular Atrial Fibrillation, has completed, sponsored by Baim Institute for Clinical Research.
- COMPLETED
- Registry status
- 817 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The study will also assess reasons for not prescribing OA to prevent thromboembolic complications in patients with NVAF seen in ambulatory care, and patients' perspectives of non-use of OA for treatment of NVAF.
Primary Outcome
This rate of OA will be based on assessment of appropriateness of OA treatment based on clinical guidelines by cardiologists using clinical data and the physician and patient surveys.
Conditions Studied
Study Locations (20)
Florida
- Clearwater Cardiovascular & Interventional Consultants MD PA - Clearwater
- Holy Cross Hospital, Inc. - Fort Lauderdale
- Heartwell LLP - Miami
- Cardiac Institute of the Palm Beaches - Palm Beach Gardens
Michigan
- Michigan Heart - St. Joseph Mercy Health System - Ann Arbor
- Munson Medical Group - Traverse City
Texas
- The Heart Institute of East Texas - Lufkin
- Waco Cardiology Associates - Waco
Virginia
- Centra Health, Inc. dba Stroobants Cardiovascular Center - Lynchburg
- Virginia Cardiovascular Specialists - Richmond
Alaska
- Alaska Heart Institute - Anchorage
California
- Orange County Heart Institute and Research Center - Orange
Illinois
- Adventist Health Partners, Inc. Amita Health - Hinsdale
Maryland
- Delmarva Heart LLC - Salisbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 817 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-09 |
What the finished NCT02919982 record still lists
NCT02919982 is an observational study that tracks outcomes without assigning an intervention. The registered 817 participants enrollment target is mid-sized for trials with a published cap, below the 109,128-participant average among 5 other Nonvalvular Atrial Fibrillation trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT02919982 names 20 study sites across 14 states, led by Florida, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT02919982 about?
NCT02919982 is a clinical study titled "Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation". The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The stud...
What is the current status of trial NCT02919982?
This trial is currently completed. The enrollment target is 817 participants. The study started on 2017-01. Estimated completion is 2019-09.
What conditions does trial NCT02919982 study?
This clinical trial studies the following conditions: Nonvalvular Atrial Fibrillation.
Who is sponsoring clinical trial NCT02919982?
This trial is sponsored by Baim Institute for Clinical Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02919982 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonvalvular Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
RECRUITING · NA
-
The CONFORMAL Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
COMPLETED
-
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia